Alignment Healthcare LLC (ALHC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Alignment Healthcare LLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 14.90 $ — 16% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIAlignment Healthcare setzt KI laut eigenen SEC-Berichten operativ in der firmeneigenen Technologieplattform AVA ein: Maschinelles Lernen und künstliche Intelligenz prognostizieren Krankenhaus-Einweisungen, Wiedereinweisungsrisiken, Mitglieder-Zufriedenheit und Kündigungsrisiken, um die Versorgung der Medicare-Advantage-Mitglieder zu steuern. KI ist damit ein internes Werkzeug zur Kostensteuerung und Versorgungskoordination, aber keine eigene Umsatzquelle - das Unternehmen verkauft Krankenversicherung, keine KI-Produkte. Die Risikofaktoren nennen den eigenen KI-Einsatz zudem ausdrücklich als operatives, regulatorisches und rechtliches Risiko, was den Befund „nutzt“ (statt „verkauft“ oder „bedroht“) stützt.
View the full file — quotes, sources, reviewed filings
„Our internal care teams and external providers use AVA, our proprietary technology platform, to coordinate high-quality care for members and manage the complexity of the healthcare system."
Unsere internen Versorgungsteams und externen Leistungserbringer nutzen AVA, unsere firmeneigene Technologieplattform, um eine hochwertige Versorgung der Mitglieder zu koordinieren und die Komplexität des Gesundheitssystems zu bewältigen.
„It also uses machine learning and artificial intelligence to help predict various scenarios such as hospital admission and re-admission risk, member satisfaction, disenrollment risk and various disease propensity scores and how to best intervene."
Sie [die AVA-Plattform] nutzt zudem maschinelles Lernen und künstliche Intelligenz, um verschiedene Szenarien vorherzusagen - etwa das Risiko von Krankenhaus-Einweisungen und Wiedereinweisungen, die Mitglieder-Zufriedenheit, das Kündigungsrisiko und diverse Krankheits-Wahrscheinlichkeitswerte - sowie um zu bestimmen, wie am besten einzugreifen ist.
„Our use of machine learning and artificial intelligence, including within our AVA platform, may introduce operational, regulatory and legal risks that could adversely affect our business, financial condition and results of operations."
Unser Einsatz von maschinellem Lernen und künstlicher Intelligenz, auch innerhalb unserer AVA-Plattform, kann operative, regulatorische und rechtliche Risiken mit sich bringen, die unser Geschäft, unsere Finanzlage und unsere Geschäftsergebnisse beeinträchtigen könnten.
Filings Reviewed: 10-Q 2026-04-30 · 10-Q 2025-10-30 · 10-Q 2025-07-30 · 10-Q 2025-05-01 · 10-K 2026-02-27 · 10-K 2025-02-27
Rated on July 10, 2026 · How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 40.2% passed
- More than 10% revenue growth is expected for the coming year 25.5% passed
- Share count grows by less than 3% a year 3.0% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 48.9% passed
- Gross margin at 40% or higher and without meaningful erosion 12.4% failed
- Goodwill from acquisitions does not grow faster than revenue 3.0% passed
- Net debt below twice EBITDA 240 m net cash passed
- Operating cash flow covers the profits of the last three years 392 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.5% passed
- Insiders hold at least 10% or are net buyers 2.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 65.2% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 11
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.50 | 0.49 – 0.50 | 5,209 | 54.0% | 4 |
| 12/31/2027 | 0.75 | 0.68 – 0.87 | 6,500 | 52.0% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.16 | – | 701 | 50.70 | -4.40 | -9 | -18 |
| 2025: Q1 | -0.05 | – | 927 | 47.50 | -1.00 | 17 | 8 |
| 2025: Q2 | 0.07 | – | 1,015 | 49.00 | 1.50 | 29 | 21 |
| 2025: Q3 | 0.02 | – | 994 | 43.50 | 0.40 | 145 | 161 |
| 2025: Q4 | -0.05 | – | 1,013 | 44.40 | -1.10 | -50 | -67 |
| 2026: Q1 | 0.05 | – | 1,235 | 33.30 | 0.90 | 129 | 121 |
| 2026: Q2 | 0.17 | 142.90 | 1,336 | 31.50 | 2.70 | -17 | -27 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 757 | -29 | -45 | -0.29 | 9 | -79 | 193 |
| 2020 | 959 | -5 | -23 | -0.12 | 8 | 31 | 339 |
| 2021 | 1,168 | -178 | -195 | -1.14 | -79 | 306 | 631 |
| 2022 | 1,434 | -129 | -150 | -0.83 | -45 | 238 | 634 |
| 2023 | 1,824 | -128 | -148 | -0.79 | -59 | 157 | 592 |
| 2024 | 2,704 | -102 | -128 | -0.67 | 35 | 100 | 782 |
| 2025 | 3,949 | 15 | -1 | 0.00 | 140 | 179 | 1,066 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Alignment Healthcare, Inc. betreibt eine verbraucherorientierte Gesundheitsplattform für Senioren in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 1,849 |
| Headquarters | Orange, CA |
| Address | 1100 West Town and Country Road, 92868 Orange, United States |
| Phone | 844 310 2247 |
| Website | alignmenthealth.com |
| IPO Date | 26. Mar 2021 |
| ISIN | US01625V1044 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John E. Kao | Founder, Chairman & CEO | 1962 |
| Joseph Samuel Konowiecki J.D. | Vice Chairman & Executive VP of Corporate Affairs | 1954 |
| Dawn Christine Maroney | President | 1968 |
| James M. Head | Chief Financial Officer | 1966 |
| Christopher J. Joyce J.D. | Chief Legal & Administrative Officer | 1964 |
| Hyong J. Kim M.D. | Chief Medical Officer | 1970 |
| Donald S. Furman M.B.A., M.D. | Co-Founder & Chief Clinical Officer | 1951 |
| Shane Hochradel | Chief Operations Officer | – |
| Robert L. Scavo | Chief Information Officer | 1965 |
| Andreas Wagner | Chief Human Resources Officer | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Maroney Dawn Christine | President | Sell | 177,068 | 20.83 | 3,687,990 |
| 15. Jul 2026 | Maroney Dawn Christine | President | Other | 152,068 | 9.06 | 1,377,736 |
| 10. Jul 2026 | Kao John E | Chief Executive Officer | Sell | 18,356 | 20.65 | 378,998 |
| 10. Jul 2026 | Kao John E | Chief Executive Officer | Sell | 279,644 | 19.81 | 5,540,363 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.